Takahiro Tanaka

Tokushima, 7708504, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Cancers

Published: September 20, 2023

A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.

A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.

Journal: Clinical journal of gastroenterology

Published: December 08, 2022

Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.

Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: June 28, 2022

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.

Journal: Cancer medicine

Published: January 30, 2022

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Journal: Cancers

Published: September 08, 2021

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: June 12, 2021

An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration.

An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration.

Journal: Internal medicine (Tokyo, Japan)

Published: January 18, 2021

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.

Journal: Medicine

Published: October 21, 2020

Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.

Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 01, 2020

Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.

Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: July 10, 2020

Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array.

Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array.

Journal: Oncotarget

Published: April 02, 2020

Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.

Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.

Journal: Journal of gastroenterology

Published: July 07, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026